Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share transactions executed on the London Stock Exchange (XLON) on July 13, 2017.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £16.2165 per share.
- Total Volume Reported: 825 shares (across three separate notifications).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of shares by insiders following the re-investment of dividends paid on July 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share purchase events.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares resulting from dividend re-investment plans.
- Parties Involved:
- Mrs. V A Whyte (Company Secretary): Acquired 91 shares.
- Mr. I W Whyte (PCA of Mrs. V A Whyte): Acquired 498 shares.
- Mrs. D Connor (PCA of Mr. R G Connor, President, Global Manufacturing & Supply): Acquired 236 shares.
- Market Data: The transactions occurred at a uniform price of £16.2165 on the London Stock Exchange.
- Financial Data Limitation: This filing does not provide any data regarding the company's overall revenue, earnings, or liquidity.